Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/28/2012

5,283$  181,906$  156,313Computation of Non-GAAP Adjusted Diluted Net Income per ShareNon-GAAP adjusted net income

$  50,611$  45,283$  181,906$  156,313Add interest expense on senior convertible notes, net of income tax

6256252,5012,501Non-GAAP adjusted diluted net income

$  51,236$  45,908$  184,407$  158,814Shares used in computing GAAP diluted net income per share

84,49390,93488,07690,081Shares used in computing Non-GAAP adjusted diluted net income per share

84,49390,93488,07690,081GAAP diluted net income  per share

$
.65$
.43$
.68$
.47Non-GAAP adjusted diluted net income  per share

$
.61$
.50$
2.09$
.76Use of Non-GAAP Financial Measures Our "non-GAAP adjusted net income" excludes the following items from GAAP net income:

1.  Non-cash interest expense: Non-GAAP adjusted net income excludes certain non-cash interest expense resulting from the change in the method of accounting for our convertible notes which became effective in 2009.  We believe that excluding the non-cash portion of our interest expense allows management and investors an alternative view of our financial results "as if" our net income reflected only the cash portion of our interest expense.  

2.  Purchase accounting and product acquisition related adjustments:  Non-GAAP adjusted net income excludes certain items related to our acquisitions. The excluded items include charges related to amortization of intangible assets arising from acquisitions, changes in the fair value of future contingent consideration and upfront fees or milestone payments under license agreements.

3.  Stock option expense: Non-GAAP adjusted net income excludes the impact of our stock compen
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... FRANCISCO , July 30, 2014 ... Congress evaluated the safety and efficacy of CSL ... rejection following kidney transplants in highly sensitized patients. ... inhibitor of the complement system. The ... in significant increases in the levels of complement ...
(Date:7/30/2014)... Geneva, Switzerland (PRWEB) July 30, 2014 ... proven technologies for biologic drug discovery and mammalian cell ... SURE CHO-Mplus Libraries ™ will be presented at ... conference being held, September 8 – 10, 2014 ... Berkeley, California. , The following abstract will be ...
(Date:7/30/2014)... 30, 2014 July 30, 2014. ... biotechnology firm that provides DNA-based authentication and security solutions ... Vice President of Life Sciences, a newly created position, ... Dr. Hogan will lead APDN’s drive to build its ... biotech and healthcare customers, provide guidance to APDN’s R&D ...
(Date:7/30/2014)... July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... Day 180 List of Outstanding Issues (LOI) from the ... Use (CHMP) for the NB32 Marketing Authorization Application (MAA). ... an investigational drug candidate being evaluated for weight loss. ... 120 time point were adequately addressed by the Company ...
Breaking Biology Technology:Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3
... plc (LSE: SHP, NASDAQ: SHPGY), the global specialty ... of,arrangement proposed in a circular to shareholders dated ... meeting convened by the Court and,held today., ... the High Court is expected to,approve the scheme ...
... - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced ... a clinical trial using intravenous administration of,REOLYSIN(R) ... well as immune modulator, in patients with ... Spicer of King,s College in London,Dr. Johann ...
... May 9 Millstone Medical Outsourcing,announced today ... 13485,certified quality system to the Memphis, TN, ... world,s largest developer and,publisher of international standards.) ... highly-experienced quality engineer, to serve as Quality ...
Cached Biology Technology:Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans 2Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans 3Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans 4Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans 5Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial 2Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial 3Millstone Medical Outsourcing Achieves Quality Advantages in Memphis: Certified ISO 13485, Hires Experienced Quality Manager 2
(Date:7/30/2014)... Long before humans figured out how to create colors, ... bright butterfly wings of many different hues, for example. ... a more environmentally friendly way to make colored plastics. ... and architectures of materials rather than dyes, to ... Letters . , N. Asger Mortensen, Anders Kristensen and ...
(Date:7/30/2014)... Chown has been awarded the Scientific Committee on ... Antarctic Research. , SCAR, an inter-disciplinary international science ... scientific research in the Antarctic region, and on ... Earth system. The organisation also provides scientific advice ... for governing the region. , The medal is ...
(Date:7/30/2014)... pieces is still in its infant stage. But it ... major significance. "Amazingly often, we are findingin addition to ... we found in Baltic amber," explained Bonn paleontologist Professor ... from the Baltic Sea region, which is almost 10,000 ... the coastal regions of Mecklenburg, Poland and Belarus. The ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2
... NOVEMBER 10, 2008 - The increasing popularity of reduced ... development in combating soil erosion, but it has also ... crop yields. For peanut crops, however, reduced ... viable practice, as findings of inconsistent yields have not ...
... report on progress towards the first Census of Marine ... astonishing examples of recent new finds from the world,s ... for the World Conference on Marine Biodiversity (Valencia, Spain ... on Marine Biodiversity and Ecosystem Functioning, the ...
... 2008) -- On Nov. 8 and 9, Morgan ... Medical Center will host an "Innovations in Pediatric ... which will feature lectures by international leading authorities ... cell therapy breakthroughs. Key topics include discoveries ...
Cached Biology News:Tillage, rotation impacts peanut crops 2Scientists announce major progress towards historic Census of Marine Life in 2010 2Innovations in Pediatric Medicine International Conference brings together pediatrics experts 2
... Quality ISO 9001:2000 Certified USDA Research ... Validated, SOP's Training AALAS Certified ... All Procedures GLP Documentation Upon Request ... shopping point for all your custom immunology ...
...
Peptide-affinity Purified Polyclonal Antibody to Sphingolipid Receptor Edg8/S1P5...
... entry by collecting data from any RS232 ... Collect is extremely easy to use and ... entry. An excellent solution for collecting ... force gauges, digital calipers, bar code readers, ...
Biology Products: